Samuel Rubinstein bought $2,150 of MDWD
director at MediWound Ltd.. 150 shares at an average of $14.33, traded May 29, 2026, filed Jun 1, 2026.
Score components
- +15RoleDirector
- 0Trade size$2k at market
- +3Relative to holdingsHoldings up 5%
- +18Price context0% above the 52-week low; 36% below the 52-week high
- +15Cluster3 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (1 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001178913-26-003002, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 29, 2026 | POpen-market purchase Ordinary Shares | +150 | $14.33 | $2,150 | 2,993 | Jun 1, 2026 |
Related signals
Other insiders at MediWound Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | MDWDbuy MediWound Ltd. | Samuel Rubinstein director | $6,626 525 shares | - | |
| 43Moderate | MediWound Ltd. | Samuel Rubinstein director | $6,678 525 shares | -100% | |
| 41Moderate | MediWound Ltd. | Shmuel Hess COO & Chief Commercial Officer | $75k 5,823 shares | -312% | |
| 60Notable | MediWound Ltd. | Nachum Shamir director | $84k 6,000 shares | +12% | |
| 58Moderate | MediWound Ltd. | David Morton Fox director | $50k 3,537 shares | +19% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.